Telithromycin: Uses, Effects and Risks
Telithromycin is an antibiotic belonging to the ketolide class, used to treat bacterial respiratory tract infections. It is effective against a broad range of pathogens.
Things worth knowing about "Telithromycin"
Telithromycin is an antibiotic belonging to the ketolide class, used to treat bacterial respiratory tract infections. It is effective against a broad range of pathogens.
What is Telithromycin?
Telithromycin is an antibiotic belonging to the ketolide class of antimicrobial agents, which are structurally derived from macrolide antibiotics. It was specifically developed to overcome bacterial resistance to classical macrolides such as erythromycin and azithromycin. Telithromycin was marketed under the brand name Ketek in Europe and the United States, but its approval has been significantly restricted or withdrawn in many countries due to serious safety concerns.
Indications
Telithromycin was originally approved for the treatment of the following bacterial respiratory tract infections in adults:
- Community-acquired pneumonia (CAP) of mild to moderate severity
- Acute exacerbation of chronic bronchitis
- Acute bacterial sinusitis
- Tonsillitis and pharyngitis caused by Streptococcus pyogenes
Due to serious adverse effects, the clinical use of telithromycin has been substantially curtailed in most countries.
Mechanism of Action
Telithromycin inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome. Compared to conventional macrolides, it binds with higher affinity at two sites on the ribosome (domains II and V of the 23S rRNA), which explains its activity against macrolide-resistant bacteria. By blocking protein synthesis, bacteria are unable to replicate, resulting in a bacteriostatic effect that allows the immune system to clear the infection.
Spectrum of Activity
Telithromycin is active against several bacteria commonly responsible for respiratory tract infections, including:
- Streptococcus pneumoniae (including penicillin- and macrolide-resistant strains)
- Haemophilus influenzae
- Moraxella catarrhalis
- Mycoplasma pneumoniae
- Chlamydophila pneumoniae
- Legionella pneumophila
Dosage
The standard adult dosage was 800 mg once daily as an oral tablet, typically for 5 to 10 days depending on the indication. Telithromycin was not recommended for use in children and adolescents under 18 years of age. Dose adjustment was required in patients with severe renal impairment.
Side Effects
Telithromycin is associated with several serious adverse effects that led to major regulatory restrictions:
- Hepatotoxicity: Severe, sometimes fatal liver damage including acute liver failure has been reported.
- Visual disturbances: Blurred vision, diplopia (double vision), and accommodation disorders, particularly in younger patients.
- Worsening of myasthenia gravis: Life-threatening deterioration of this neuromuscular condition has been documented.
- Cardiotoxicity: Prolongation of the QT interval on ECG, which may lead to serious cardiac arrhythmias.
- Common side effects: Nausea, vomiting, diarrhea, headache, and dizziness.
Contraindications
Telithromycin must not be used in patients with:
- Known hypersensitivity to telithromycin, other ketolides, or macrolide antibiotics
- Myasthenia gravis or a history of drug-induced respiratory failure due to myasthenia gravis
- Severe hepatic impairment or a history of drug-induced liver injury caused by telithromycin
- Concomitant use of cisapride or pimozide (risk of QT prolongation)
Drug Interactions
Telithromycin is metabolized by the hepatic enzyme CYP3A4 and simultaneously acts as a potent inhibitor of this enzyme, leading to clinically significant drug interactions:
- Statins (e.g., simvastatin, lovastatin): Increased risk of muscle damage (rhabdomyolysis)
- Immunosuppressants (e.g., ciclosporin, tacrolimus): Elevated plasma levels of these agents
- Anticoagulants (e.g., warfarin): Altered coagulation parameters
- Ergot-containing medications: Risk of vasospasm and ergotism
Regulatory Status and Clinical Relevance
Telithromycin (Ketek) was approved in both the EU and the USA, but following multiple reports of severe hepatotoxicity and other serious adverse events, it was withdrawn from the market or had its indications substantially reduced in many countries. Both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) issued safety warnings and label revisions. Today, telithromycin has minimal clinical relevance, as safer and equally effective alternatives are available for the treatment of respiratory tract infections.
References
- European Medicines Agency (EMA): Ketek (Telithromycin) - Summary of Product Characteristics. EMA, 2007.
- Zhanel GG et al. - The Ketolides: A Critical Review. Drugs, 2002; 62(12): 1771-1804.
- Bertram G. Katzung: Basic and Clinical Pharmacology. 14th Edition. McGraw-Hill Education, 2018.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryVisual Acuity Reduction
Diogenes Syndrome
liver cirrhosis curable
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Telithromycin-en